Rationale and design of the cyclosporine in Takotsubo syndrome (CIT) trial.
Bastian Bruns, Nesrin Elsous, Ina Burghaus...
https://pubmed.ncbi.nlm.nih.gov/40268179/Actively Recruiting
Led by University Hospital Heidelberg · Updated on 2026-05-01
204
Participants Needed
24
Research Sites
52 weeks
Total Duration
This research aims to study the effects of repetitive acute Cyclosporine A CsA bolus therapy in patients with Takotsubo syndrome TTS who have a high risk of poor outcomes. Takotsubo syndrome may be caused by excess catecholamines leading to heart inflammation and damage. Currently, there is no proven treatment for TTS, and this phase 2 randomized controlled trial will evaluate whether CsA can reduce heart injury and improve heart function compared to placebo. Participants will be randomly assigned to receive either Cyclosporine A or a placebo intravenously at baseline, 12 hours, and 24 hours after study inclusion. The treatment is given as a bolus dose based on body weight. The study will compare these two groups to see if CsA reduces heart muscle damage and improves the hearts ejection fraction. Secondary measures include heart inflammation, hospital stay length, and quality of life over a one-year follow-up. During the study, participants will have blood tests to measure heart damage markers like Troponin T at multiple time points up to 30 days. Heart function and inflammation will be assessed through imaging and clinical evaluations. Researchers will monitor participants for cardiovascular events, symptoms, depression, anxiety, and PTSD scores at 30 days and one year. The total participation includes close monitoring during the acute phase and follow-up assessments for one year.
CONDITIONS
Cyclosporine In Takotsubo Syndrome
B
Bastian Bruns, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University Hospital Heidelberg
Lead Sponsor
German Centre of Cardiovascular Research (DZHK)
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 24 hours
Participants receive intravenous bolus doses of Cyclosporine A or placebo at baseline, 12 hours, and 24 hours after enrollment to assess effects on myocardial damage and cardiac function.
3 dosing visits within 24 hours
Duration - 1 year
Participants are monitored for recovery of cardiac function, symptom burden, psychosocial assessments, and clinical outcomes including cardiovascular events up to 1 year after treatment.
Follow-up visits at 30 days and 1 year
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Bastian Bruns, Nesrin Elsous, Ina Burghaus...
https://pubmed.ncbi.nlm.nih.gov/40268179/University Hospital Heidelberg
Lead Sponsor
German Centre of Cardiovascular Research (DZHK)
Collaborating Sponsor